cladribine has been researched along with Encephalitis, JC Polyomavirus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbadessa, G; Avolio, C; Barone, S; Bonavita, S; Buccafusca, M; Callari, G; Capuano, R; Curti, E; D'Amico, E; Di Francescantonio, V; Ferraro, D; Gallo, A; Granella, F; Lanzillo, R; Lucchini, M; Lus, G; Mirabella, M; Patti, F; Petracca, M; Pontillo, G; Signoriello, E; Sola, P; Valentino, P; Zanghì, A | 1 |
| Acker, T; Berghoff, M; Dassinger, B; Gizewski, ER; Grams, A; Hildebrandt, GC; Kaps, M; Klappstein, G; Schänzer, A | 1 |
1 trial(s) available for cladribine and Encephalitis, JC Polyomavirus
| Article | Year |
|---|---|
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Cladribine; Drug Substitution; Female; Follow-Up Studies; Humans; Immunologic Factors; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Retrospective Studies; Risk Factors; Rituximab; Young Adult | 2021 |
1 other study(ies) available for cladribine and Encephalitis, JC Polyomavirus
| Article | Year |
|---|---|
Development of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma 13 years after treatment with cladribine.
Topics: Antineoplastic Agents; Cladribine; Female; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Middle Aged | 2013 |